Third quarter 2017 report
Final results of the dose-escalation part from the phase I trial evaluating IPH4102 in patients with advanced cutaneous T-cell lymphomas presented at the EORTC CLTF meeting
First half of 2017: delivering key clinical data and strengthening the pipeline
ICI conference 2017: new preclinical data further strengthen the rationale of IPH5401 and monalizumab for cancer treatments and in combination with anti-PD-1/PD-L1
Number of shares and voting rights of Innate Pharma as at August 4, 2017
Issuance by Innate Pharma of 3,343,748 ordinary shares to Novo Nordisk A/S in consideration for rights in anti-C5aR
Results of Annual General Meeting and changes to Innate Pharma’s governance and management team
Dose-escalation data show favorable safety profile and promising clinical activity for IPH4102
Innate Pharma strengthens its proprietary pipeline with the acquisition of anti-C5aR, a first-in-class clinical-stage antibody,from Novo Nordisk A/S
Innate Pharma to hold its Annual General Meeting of shareholders on June 23, 2017
